Literature DB >> 26536862

A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.

Raoul Orvieto1,2.   

Abstract

Recently, several new promising modifications have been introduced to clinical practice that may simplify and optimize IVF outcome. In the present opinion paper we present a simplified approach to controlled ovarian hyperstimulation protocol (COH), which combines the benefits of the ultrashort flare GnRH agonist/GnRH antagonist protocol and the personalized tailored mode and timing of ovulation triggering, aiming to improve IVF outcome while eliminating of severe OHSS.In patients at risk to develop severe ovarian hyperstimulation syndrome (OHSS), GnRH agonist (GnRHa) trigger if offered for final follicular maturation. While in those achieving ≥20 oocytes, the freeze all policy with the subsequent frozen-thawed embryo transfers (ET) is recommended, in those where less than 20 oocytes are retrieved, patients are re-evaluated 3 days after oocyte retrieval (day of ET) for signs of early moderate OHSS. If no early signs of OHSS developed, one embryo was transferred, and the patients are instructed to inject 1500 IU of HCG. In cases where signs of early moderate OHSS appear, the freeze all policy is recommended.In Patients not at risk to develop severe OHSS- three different modes of concomitant administration of both GnRHa and a standard bolus of hCG (5000-10,000 units) prior to oocyte retrieval were suggested. Standard hCG dose concomitant with GnRHa (dual trigger), 35-37 h before oocyte retrieval is offered to normal responders patients, resulting in improved oocyte/embryo quality and IVF outcome. GnRHa 40 h and standard hCG added 34 h prior to oocyte retrieval (double trigger), respectively are offered to patients demonstrating abnormal final follicular maturation despite normal response to COH. The double trigger results in significantly higher number of oocytes retrieved, higher proportions of the number of oocytes retrieved to the number of follicles >10 mm and >14 mm in diameter on day of hCG administration, higher number of MII oocytes and proportion of MII oocytes per number of oocytes retrieved, with the consequent significantly increased number of top-quality embryos, as compared to the hCG-only trigger cycles. Standard hCG dose concomitant with GnRHa (dual trigger), 34 h before oocyte retrieval should be offered to poor responders patients, aiming to overcome premature luteinization, while achieving high yield of mature oocytes.Further studies are required to support this new concept prior to its implementation as a universal COH protocol to IVF practice.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26536862      PMCID: PMC4632684          DOI: 10.1186/s13048-015-0198-3

Source DB:  PubMed          Journal:  J Ovarian Res        ISSN: 1757-2215            Impact factor:   4.234


  32 in total

1.  Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.

Authors:  Ming-Huei Lin; Frank Shao-Ying Wu; Robert Kuo-Kuang Lee; Sheng-Hsiang Li; Shyr-Yeu Lin; Yuh-Ming Hwu
Journal:  Fertil Steril       Date:  2013-08-28       Impact factor: 7.329

2.  Triggering final follicular maturation--hCG, GnRH-agonist or both, when and to whom?

Authors:  Raoul Orvieto
Journal:  J Ovarian Res       Date:  2015-08-21       Impact factor: 4.234

3.  A novel approach to normal responder patient with repeated implantation failures--a case report.

Authors:  Raoul Orvieto; Masha Brengauz; Baruch Feldman
Journal:  Gynecol Endocrinol       Date:  2015-03-03       Impact factor: 2.260

4.  Women with poor response to IVF have lowered circulating gonadotrophin surge-attenuating factor (GnSAF) bioactivity during spontaneous and stimulated cycles.

Authors:  Francisca Martinez; P N Barri; B Coroleu; R Tur; Tarja Sorsa-Leslie; William J Harris; Nigel P Groome; Philip G Knight; Paul A Fowler
Journal:  Hum Reprod       Date:  2002-03       Impact factor: 6.918

5.  Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for in vitro fertilization.

Authors:  Raoul Orvieto; Neri Laufer
Journal:  Fertil Steril       Date:  2014-10-01       Impact factor: 7.329

Review 6.  GnRH agonist versus GnRH antagonist in ovarian stimulation: an ongoing debate.

Authors:  Raoul Orvieto; Pasquale Patrizio
Journal:  Reprod Biomed Online       Date:  2012-11-07       Impact factor: 3.828

7.  Co-administration of GnRH-agonist and hCG for final oocyte maturation (double trigger) in patients with low number of oocytes retrieved per number of preovulatory follicles--a preliminary report.

Authors:  Jigal Haas; Eran Zilberberg; Shir Dar; Alon Kedem; Ronit Machtinger; Raoul Orvieto
Journal:  J Ovarian Res       Date:  2014-08-02       Impact factor: 4.234

8.  LH and hCG action on the same receptor results in quantitatively and qualitatively different intracellular signalling.

Authors:  Livio Casarini; Monica Lispi; Salvatore Longobardi; Fabiola Milosa; Antonio La Marca; Daniela Tagliasacchi; Elisa Pignatti; Manuela Simoni
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

9.  HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept.

Authors:  Jigal Haas; Alon Kedem; Ronit Machtinger; Shir Dar; Ariel Hourvitz; Gil Yerushalmi; Raoul Orvieto
Journal:  J Ovarian Res       Date:  2014-04-03       Impact factor: 4.234

10.  Ovarian hyperstimulation syndrome- an optimal solution for an unresolved enigma.

Authors:  Raoul Orvieto
Journal:  J Ovarian Res       Date:  2013-11-05       Impact factor: 4.234

View more
  5 in total

1.  Triggering final follicular maturation: hCG, GnRH-agonist, or both, when and to whom?

Authors:  Raoul Orvieto
Journal:  J Assist Reprod Genet       Date:  2017-06-27       Impact factor: 3.412

2.  Triggering final follicular maturation-hCG, GnRH-agonist or both, when and to whom?

Authors:  Raoul Orvieto
Journal:  J Assist Reprod Genet       Date:  2016-07-22       Impact factor: 3.412

3.  The in-vitro effect of gonadotropins' type and combination on Granulosa cells gene expressions.

Authors:  Yuval Yung; Adva Aizer; Sarah Tieb; Sharon Avhar Maydan; Ettie Maman; Lilach Marom Haham; Jigal Haas; Raoul Orvieto
Journal:  Reprod Biol Endocrinol       Date:  2022-09-24       Impact factor: 4.982

4.  Coronavirus disease 2019 vaccination and infertility treatment outcomes.

Authors:  Sarit Avraham; Alon Kedem; Hilli Zur; Michal Youngster; Odelia Yaakov; Gil M Yerushalmi; Itai Gat; Yariv Gidoni; Alyssa Hochberg; Micha Baum; Ariel Hourvitz; Ettie Maman
Journal:  Fertil Steril       Date:  2022-02-25       Impact factor: 7.490

5.  Optimising Follicular Development, Pituitary Suppression, Triggering and Luteal Phase Support During Assisted Reproductive Technology: A Delphi Consensus.

Authors:  Raoul Orvieto; Christos A Venetis; Human M Fatemi; Thomas D'Hooghe; Robert Fischer; Yulia Koloda; Marcos Horton; Michael Grynberg; Salvatore Longobardi; Sandro C Esteves; Sesh K Sunkara; Yuan Li; Carlo Alviggi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-10       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.